Compare CubeSmart (CUBE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Summit Therapeutics Inc — how do they compare? CubeSmart trades at $37.76 (market cap $8.45B), while Summit Therapeutics Inc trades at $17.35 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and CubeSmart pays a 5.65% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Summit Therapeutics Inc for 16 Days on average.
| CUBE | SMMT | |
|---|---|---|
Market Cap | $8.45B | $13.71B |
Volume | 2,879,532 | 6,173,057 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $26.38 |
52-Week Low | $35.36 | $12.43 |
Typical Hold Time | 89 Days | 16 Days |
Enterprise Value | $11.97B | $13.04B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CUBE trades at $37.23, down 1.4% on the day, with a bearish technical signal and mixed earnings history including a Q2 2026 FFO miss. The company maintains strong profitability with a 29.41% net income margin and a 5.4% dividend yield, but faces headwinds from moderating revenue growth and high leverage.
The outlook is cautiously optimistic with a consensus price target of $44.00, though risks include elevated debt levels and sector oversupply. Upside hinges on operational improvements and a return to earnings growth in H2 2026 as guided.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
